Notably, both glycolysis inhibitors achieved a significant dose-dependent decrease in intracellular lactate (Fig. 2b, c), as well as global lactylation and H3K18la levels (Fig. 2d, e) in ocular melanoma cells (OCM1 and CRMM1 cells). This evidence concerns the gene OCM and ocular melanoma.